Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

BACKGROUND: Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage. METHODS: In the CLARITY study (ClinicalTrials.gov NCT00213135), the effect of 2 years’ treatment with cladribin...

Descripción completa

Detalles Bibliográficos
Autores principales: De Stefano, Nicola, Giorgio, Antonio, Battaglini, Marco, De Leucio, Alessandro, Hicking, Christine, Dangond, Fernando, Giovannoni, Gavin, Sormani, Maria Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818021/
https://www.ncbi.nlm.nih.gov/pubmed/28140753
http://dx.doi.org/10.1177/1352458517690269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818021/
https://www.ncbi.nlm.nih.gov/pubmed/28140753
http://dx.doi.org/10.1177/1352458517690269

Ejemplares similares